ALXO — ALX Oncology Holdings Inc.

ALXO Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash Balance: ALXO reported a total cash balance of $67 million, expected to provide runway into Q1 2027.
• Financial Discipline: The company emphasized maintaining tight control over capital as they prepare for upcoming data milestones.

2. Strategic Updates and Business Highlights

• Evorpacept Development: The ASPEN-06 trial data presented at SITC highlighted CD47 expression as a predictive biomarker for durable clinical responses in HER2-positive gastric cancer. Patients with high CD47 expression showed significantly improved outcomes across key efficacy metrics (e.g., overall response rate (ORR) of 65% vs. 26% in controls).
• ALX2004 Progress: The novel EGFR-targeted antibody-drug conjugate (ADC) ALX2004 is currently in a Phase I trial, with the first patient dosed in August 2025. The trial is progressing well, with initial safety data expected in H1 2026.
• Market Opportunity: The potential market for evorpacept in HER2-positive breast cancer is estimated at $2 billion to $4 billion, targeting approximately 20,000 patients who are both HER2-positive and CD47 high.

3. Forward Guidance and Outlook

• Clinical Milestones: ALXO is focused on driving evorpacept into the ASPEN-Breast study, with the first patient expected to be dosed in Q4 2025 and interim data anticipated in Q3 2026. For ALX2004, initial safety data is expected in the first half of 2026.
• Strategic Focus: The company aims to leverage the CD47 biomarker to select patients for future trials, enhancing the potential for successful outcomes.

4. Bad News, Challenges, or Points of Concern

• Competitive Landscape: The evolving treatment landscape for HER2-positive breast cancer poses challenges, particularly with the introduction of new therapies like trastuzumab deruxtecan (T-DXd), which may impact the positioning of evorpacept.
• Regulatory and Development Risks: The need for a companion diagnostic for CD47 expression could introduce delays or complications in clinical development and regulatory approval processes.

5. Notable Q&A Insights

• CD47 Expression Correlation: Management discussed the correlation between CD47 positivity in gastric and breast cancer, indicating a consistent prevalence of high CD47 expression across studies.
• Companion Diagnostic Development: ALXO is working with partners to develop a companion diagnostic for CD47, with plans to operationalize this process ahead of a Phase III trial.
• Efficacy Benchmarks: The company aims for a response rate of 35% to 40% in the upcoming breast cancer trial, which would be a significant improvement over existing treatments that show lower response rates, particularly in the post-ENHERTU setting.

Overall, ALXO's Q3 2025 earnings call highlighted significant clinical advancements and a strong financial position, while also addressing competitive pressures and the importance of biomarker-driven strategies in their development pipeline.